<a id="isi"></a>
<div class="disclaimer">
    <h6><strong>Indication and Limitations of Use</strong></h6>
    <p>VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.</p>
    <ul>
        <li>The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.</li>
        <li>The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.</li>
    </ul>
    <h6><strong>Important Safety Information for VASCEPA</strong></h6>
    <ul>
        <li>VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.</li>
        <li>Use with caution in patients with known hypersensitivity to fish and/or shellfish.</li>
        <li>The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia (2.3% VASCEPA, 1.0% placebo).</li>
        <li>Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.</li>
        <li>In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.</li>
        <li>Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA.</li>
        <li>Adverse events may be reported by calling 1-855-VASCEPA or the FDA&nbsp;at 1‑800‑FDA‑1088.</li>
    </ul>
    <p><strong>See full <a href="../includes/uploads/vascepa-pi-ppi-clean-P00120G-1-15.pdf" target="_blank">Prescribing Information</a> for more information on VASCEPA.</strong></p>
</div>